Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


Selecta Enters into an Exclusive License Agreement with Genovis to

Shots: Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on sales globally & holds the rights for research, preclinical, diagnostic & other non-therapeutic applications of Xork The collaboration will utilize Genovis’ IgG protease, IdeXork (Xork & Selecta’s ImmTOR platform for […]Read More


Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to

Shots: BehaVR to receive $5M up front, ~$18M in development milestone and R&D support along with commercial & operational support fees and is eligible to receive $140M in milestone upon commercial success along with royalties on global sales of the digital therapeutic products The collaboration combines BehaVR’s development capabilities with SDP’s expertise to develop prescription […]Read More